<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623944</url>
  </required_header>
  <id_info>
    <org_study_id>NKX101-101</org_study_id>
    <nct_id>NCT04623944</nct_id>
  </id_info>
  <brief_title>NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS</brief_title>
  <official_title>A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nkarta Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nkarta Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center, Phase 1 study to determine safety and&#xD;
      tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting&#xD;
      NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high&#xD;
      risk relapsed/refractory MDS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-finding study of NKX101 and will be conducted in 2 parts:&#xD;
&#xD;
      Part 1: dose finding with two dosing regimens, utilizing modified &quot;3+3&quot; enrollment schema.&#xD;
&#xD;
      Part 2: dose expansion to further evaluate safety and tolerability, cellular kinetics,&#xD;
      pharmacodynamics and anti-tumor response in expansion cohorts of patients with either AML or&#xD;
      MDS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2020</start_date>
  <completion_date type="Anticipated">July 2038</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>30 days after last dose of NKX101</time_frame>
    <description>Incidence, nature, and severity of treatment related adverse events will be evaluated. An adverse event is any unfavorable and unintended sign including clinically significant abnormal laboratory findings, symptom or disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects experiencing dose-limiting toxicities of NKX101</measure>
    <time_frame>28 days from first dose of NKX101</time_frame>
    <description>DLTs are defined as adverse events attributable to NKX101 treatment that occur during Cycle 1 and meet protocol-specified criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of NKX101 half-life</measure>
    <time_frame>28 days from first dose of NKX101</time_frame>
    <description>Time required for 50% reduction from maximum amount of circulating NKX101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NKX101 duration of persistence</measure>
    <time_frame>Followed up to 2 years after last dose of NKX101</time_frame>
    <description>Testing NKX101 in peripheral blood every 3 months after dosing to determine persistence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of host immune response against NKX101</measure>
    <time_frame>Followed up to 2 years after last dose of NKX101</time_frame>
    <description>Serum samples will be measured for antibodies against NKX101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate to NKX101</measure>
    <time_frame>Primary assessment: 28 days after first dose of NKX101 followed up to 2 years after last dose of NKX101</time_frame>
    <description>Percentage of subjects with complete and partial response. AML subjects will be assessed for anti-tumor activity of NKX101 based on the updated ELN criteria (Döhner 2017). Subjects with MDS will be assessed for anti-tumor activity of NKX101 based on the IWG criteria with MDS (Cheson 2006).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Relapsed/Refractory AML</condition>
  <condition>AML, Adult</condition>
  <condition>MDS</condition>
  <condition>Refractory Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>NKX101 - CAR NK cell therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 or 2 weekly doses of NKX101. Regimen A will dose on Day 0, 7, and 14 of a 28-day cycle. Regimen B will dose on Day 0 and 7 of a 28-day cycle.&#xD;
Part 1: either haplo-matched related donor derived or unrelated off-the-shelf donor derived NKX101 will be used&#xD;
Part 2: either haplo-matched related donor derived or unrelated off-the-shelf donor derived NKX101 will be used</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NKX101 - CAR NK cell therapy</intervention_name>
    <description>NKX101 is an investigational allogeneic CAR NK product targeting NKG2D ligands on cancer cells. The starting dose of NKX101 in Part 1/Regimen A is 1 × 10^8 NK cells (2 × 10^6/kg for patients &lt; 50 kg) administered as 3 weekly doses. The starting dose of NKX101 in Part 1/Regimen B is 1.5 × 10^8 NK cells (3 × 10^6/kg for patients &lt; 50 kg) administered as 2 weekly doses. Part 2 will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX101 as determined in Part 1.</description>
    <arm_group_label>NKX101 - CAR NK cell therapy</arm_group_label>
    <other_name>Cyclophosphamide</other_name>
    <other_name>Fludarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General:&#xD;
&#xD;
               -  ECOG performance status ≤2&#xD;
&#xD;
               -  Haplo-matched related subjects require a suitable haplo-matched related donor,&#xD;
                  who is able and willing to undergo leukapheresis&#xD;
&#xD;
          -  Disease related:&#xD;
&#xD;
               -  For AML subjects:&#xD;
&#xD;
                    -  Previously treated relapsed/refractory AML, including subjects with MRD+&#xD;
                       disease&#xD;
&#xD;
                    -  White blood cell count of ≤25 × 10^9/L&#xD;
&#xD;
               -  For MDS subjects:&#xD;
&#xD;
                    -  Intermediate-, high-, or very high-risk MDS&#xD;
&#xD;
                    -  Previously treated relapsed/refractory MDS&#xD;
&#xD;
          -  Adequate Organ Function&#xD;
&#xD;
          -  Platelet count ≥30,000/uL (platelet transfusions acceptable)&#xD;
&#xD;
          -  Other:&#xD;
&#xD;
               -  Signed informed consent&#xD;
&#xD;
               -  Agree to use an effective barrier method of birth control&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Disease related:&#xD;
&#xD;
               -  Acute promyelocytic leukemia with t(15;17) (q22;q12); or abnormal promyelocytic&#xD;
                  leukemia/retinoic acid receptor alpha (APML-RARA)&#xD;
&#xD;
               -  Evidence of leukemic meningitis or known active central nervous system disease&#xD;
&#xD;
               -  Use of any anti-AML/MDS chemotherapeutic or targeted small molecule drug within&#xD;
                  protocol specified window prior to the first dose of NKX101&#xD;
&#xD;
               -  Presence of residual non-hematologic toxicity from prior therapies that has not&#xD;
                  resolved to ≤ Grade 1&#xD;
&#xD;
               -  Any hematopoietic cell transplantation within 16 weeks&#xD;
&#xD;
          -  Other comorbid conditions and concomitant medications prohibited as per study protocol&#xD;
&#xD;
          -  Other:&#xD;
&#xD;
               -  Pregnant or lactating female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minoti Hiremath, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nkarta Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minoti Hiremath, MD, PhD</last_name>
    <phone>+1 415-651-5080</phone>
    <email>medmonitor@nkartatx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cornell Chang</last_name>
    <phone>+1 415-651-5060</phone>
    <email>clinops@nkartatx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Rotta</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Marcello Rotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tolu Adewuya</last_name>
      <phone>404-778-1900</phone>
      <email>winshipcelltherapy@emory.edu</email>
    </contact>
    <investigator>
      <last_name>William Blumm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic - Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Navneet Majhail, MD</last_name>
      <email>majhain@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Navneet Majhail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon at TriStar Bone Marrow Transplant Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Bachier</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Bachier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center, University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Bivins</last_name>
      <phone>713-794-4460</phone>
      <email>cbibins@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Gautam Borthakur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>November 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NKG2D</keyword>
  <keyword>CAR</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Natural killer</keyword>
  <keyword>ACR</keyword>
  <keyword>NKX101</keyword>
  <keyword>IL15</keyword>
  <keyword>Interleukin 15</keyword>
  <keyword>NK cell</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Adoptive cell therapy</keyword>
  <keyword>r/r AML</keyword>
  <keyword>Off-the-shelf</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

